BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CSPC Pharmaceutical Group readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies CSPC Pharmaceutical Group's drugs
  run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06751485-9179@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Anbenitamab repodatecan: Phase 3 readout est. (NCT06751485)
DESCRIPTION:Anbenitamab repodatecan\, phase 3.\nStudy: JSKN003 in Platinum-
 Resistant\, Relapsed Epithelial Ovarian Cancer\nEstimated primary completi
 on: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /anbenitamab-repodatecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06751485
URL:https://assetmemo.bio/drug/anbenitamab-repodatecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943950-1927@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:SYHX1901: Phase 3 readout est. (NCT06943950)
DESCRIPTION:SYHX1901\, phase 3\, Psoriasis.\nStudy: A Phase III Study of SY
 HX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis\nEs
 timated primary completion: 28 April 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/syhx1901#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06943950
URL:https://assetmemo.bio/drug/syhx1901#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07695597-1097@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:SYH2070: Phase 2 readout est. (NCT07695597)
DESCRIPTION:SYH2070\, phase 2\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemi
 a\nEstimated primary completion: 30 April 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/syh2070#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07695597
URL:https://assetmemo.bio/drug/syh2070#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06562894-1927@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:SYHX1901: Phase 2 readout est. (NCT06562894)
DESCRIPTION:SYHX1901\, phase 2.\nStudy: Study to Evaluate Safety and Effica
 cy of SYHX1901 Tablets in Severe Alopecia Areata Patients\nEstimated prima
 ry completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/syhx1901#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06562894
URL:https://assetmemo.bio/drug/syhx1901#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07591298-1097@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20270916
DTEND;VALUE=DATE:20270917
SUMMARY:SYH2070: Phase 2 readout est. (NCT07591298)
DESCRIPTION:SYH2070\, phase 2\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH207
 0 Injection in Participants With Homozygous Familial Hypercholesterolemia\
 nEstimated primary completion: 16 September 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/syh2070#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07591298
URL:https://assetmemo.bio/drug/syh2070#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07421284-1056@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SYH2053: Phase 3 readout est. (NCT07421284)
DESCRIPTION:SYH2053\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Study to Evaluate the Safety\, Efficacy of SYH2053 in Chinese Parti
 cipants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on
  a Background of Lipid-lowering Therapy\nEstimated primary completion: 31 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/syh205
 3#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 421284
URL:https://assetmemo.bio/drug/syh2053#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07421297-1056@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SYH2053: Phase 3 readout est. (NCT07421297)
DESCRIPTION:SYH2053\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Study to Evaluate the Safety\, Efficacy of SYH2053 as Monotherapy i
 n Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyp
 erlipidemia\nEstimated primary completion: 31 December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/syh2053#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07421297
URL:https://assetmemo.bio/drug/syh2053#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07465263-1056@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:SYH2053: Phase 3 readout est. (NCT07465263)
DESCRIPTION:SYH2053\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Study to Evaluate the SYH2053 Injection in Patients With Heterozygo
 us Familial Hypercholesterolemia (HeFH)\nEstimated primary completion: 28 
 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/syh205
 3#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 465263
URL:https://assetmemo.bio/drug/syh2053#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07640217-1078@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:SYH2068: Phase 2 readout est. (NCT07640217)
DESCRIPTION:SYH2068\, phase 2\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Phase II Clinical Study of SYH2068 Injection in Adults With Elevate
 d Lipoprotein(a)\nEstimated primary completion: 30 March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/syh2068#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07640217
URL:https://assetmemo.bio/drug/syh2068#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
